Drug Profile
Azacitidine/cedazuridine - Astex Pharmaceuticals
Alternative Names: ASTX-030Latest Information Update: 29 Jan 2024
Price :
$50
*
At a glance
- Originator Astex Pharmaceuticals
- Developer Astex Pharmaceuticals; Otsuka Pharmaceutical
- Class Antineoplastics; Aza compounds; Pyrimidine nucleosides; Ribonucleosides; Small molecules
- Mechanism of Action Antimetabolites; Cytidine deaminase inhibitors; DNA methylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 09 Dec 2023 Adverse vent and pharmacokinetics data from phase I trial in Myelodysplastic syndromes presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 22 Nov 2022 Azacitidine/cedazuridine is still in phase II/III trials for Acute myeloid leukaemia (First-line therapy) in USA (NCT04256317)
- 22 Nov 2022 Azacitidine/cedazuridine is still in phase II/III trials for Chronic myeloid leukaemia in USA (NCT04256317)